Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial

Medicine (United States)

Volumn 95, Issue 28, 2016, Pages

  Wang, Dongming ^a   Li, Wenzhen ^a   Xiao, Yang ^a   He, Wulong ^b   Wei, Weiquan ^a   Yang, Longyu ^a   Yu, Jincong ^a   Song, Fujian ^c   Wang, Zengzhen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Public Security Bureau   (China)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

mental symptom; new type drug dependence; sleep disorders; tryptophan

Indexed keywords

KETAMINE; METHAMPHETAMINE; PLACEBO; TRYPTOPHAN;

ADULT; ARTICLE; ATHENS INSOMNIA SCALE AND SYMPTOM CHECK LIST 90; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEROIN DEPENDENCE; HUMAN; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; METHAMPHETAMINE DEPENDENCE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP DISORDER ASSESSMENT; SYMPTOM CHECKLIST 90; THORAX PAIN; TREATMENT DURATION; CHEMICALLY INDUCED; CHINA; PSYCHOLOGY; QUESTIONNAIRE; SLEEP WAKE DISORDERS; TREATMENT OUTCOME;

ADULT; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; SLEEP WAKE DISORDERS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 84980001047     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004135     Document Type: Article

References (43)

1. Yang X, Xia G. Causes and consequences of increasing club drug use in China: a descriptive assessment. Subst Use Misuse 2010;45:224-39.
2. Drugs UNOo, Crime, Ctr, V.I., Austria. Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs. Asia and the Pacific; 2010: 12-17.
3. Guerreiro DF, Carmo AL, da Silva JA, et al. Club drugs. Acta Med Port 2011;24:739-56.
4. Gahlinger PM. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. Am Fam Physician 2004;69:2619-26.
5. Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 2008;27:229-35.
6. Lea T, Reynolds R, de Wit J. Alcohol and other drug use, club drug dependence and treatment seeking among lesbian, gay and bisexual young people in Sydney. Drug Alcohol Rev 2013;32:303-11.
7. McKetin R, Kozel N, Douglas J, et al. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008;27:220-8.
8. Zuckerman MD, Boyer EW. HIV and club drugs in emerging adulthood. Curr Opin Pediatr 2012;24:219-24.
9. Zhang Y, Lu C, Zhang J, et al. Gender differences in abusers of amphetamine-type stimulants and ketamine in Southwestern China. Addict Behav 2013;38:1424-30.
10. Rao U. Links between depression and substance abuse in adolescents: neurobiological mechanisms. Am J Prev Med 2006;31:S161-74.
11. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008;27:253-62.
12. Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. Can Med Assoc J 2001;164:817-21.
13. Sharp T, Cowen PJ. 5-HT and depression: is the glass half-full? Curr Opin Pharmacol 2011;11:45-51.
14. Anderson AL, Li SH, Biswas K, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012;120:135-41.
15. Coffin PO, Santos GM, Das M, et al. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebocontrolled trial. Addiction (Abingdon, England) 2013;108:751-61.
16. Young SN, Gauthier S. Tryptophan availability and the control of 5-hydroxytryptamine and tryptamine synthesis in human CNS. Adv Exp Med Biol 1981;133:221-30.
17. Yuwiler A, Brammer GL, Morley JE, et al. Short-term and repetitive administration of oral tryptophan in normal men. Effects on blood tryptophan, serotonin, and kynurenine concentrations. Arch Gen Psychiatry 1981;38:619-26.
18. Attenburrow MJ, Williams C, Odontiadis J, et al. Acute administration of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology 2003;169:104-7.
19. Minet-Ringuet J, Le Ruyet PM, Tome D, et al. A tryptophan-rich protein diet efficiently restores sleep after food deprivation in the rat. Behav Brain Res 2004;152:335-40.
20. van Dalfsen JH, Markus CR. Interaction between 5-HTTLPR genotype and cognitive stress vulnerability on sleep quality: effects of sub-chronic tryptophan administration. Int J Neuropsychopharmacol 2015;18:1-9.
21. Silber BY, Schmitt JA. Effects of tryptophan loading on human cognition, mood, and sleep. Neurosci Biobehav Rev 2010;34:387-407.
22. Ohmura Y, Jutkiewicz EM, Yoshioka M, et al. 5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal. J Pharmacol Sci 2011;117:121-4.
23. Chen D, Liu Y, He W, et al. Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts. J Huazhong Univ Science Technolog Med Sci 2012;32:422-7.
24. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000;48:555-60.
25. Sterling Publishing Company, Inc, Braverman ER. The Edge Effect: Achieve Total Health and Longevity with the Balanced Brain Advantage. 2005;154-167.
26. Meyers S. Use of neurotransmitter precursors for treatment of depression. Altern Med Rev 2000;5:64-71.
27. Rounsaville BJ, Glazer W, Wilber CH, et al. Short-term interpersonal psychotherapy in methadone-maintained opiate addicts. Arch Gen Psychiatry 1983;40:629-36.
28. Tan H, Lan XM, Yu NL, et al. Reliability and validity assessment of the revised Symptom Checklist 90 for alopecia areata patients in China. J Dermatol 2015;42:975-80.
29. Chung KF, Kan KK, Yeung WF. Assessing insomnia in adolescents: comparison of Insomnia Severity Index, Athens Insomnia Scale and Sleep Quality Index. Sleep Med 2011;12:463-70.
30. Haver B. Screening for psychiatric comorbidity among female alcoholics: the use of a questionnaire (SCL-90) among women early in their treatment programme. Alcohol Alcohol 1997;32:725-30.
31. Vincent N, Schoobridge J, Ask A, et al. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug Alcohol Rev 1998;17:187-95.
32. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004;13:181-90.
33. Heinzerling KG, Swanson AN, Kim S, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010;109:20-9.
34. Sulaiman AH, Gill JS, Said MA, et al. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract 2013;17:131-8.
35. Benca RM, Peterson MJ. Insomnia and depression. Sleep Med 2008;9: S3-9.
36. Volkow ND, Wang GJ, Fowler JS, et al. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 2011;108:15037-42.
37. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008;33:1162-70.
38. Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction (Abingdon, England) 2010;105:146-54.
39. Zhang Y, Xu Z, Zhang S, et al. Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. J Psychiatr Res 2014;53:99-102.
40. Zhang Y, Wang Y, Zeng H. Analysis of four new drugs abuse in Beijing. Chin J Drug Depend 2008;5:367-72.
41. Ding Y, He N, Detels R. Circumstances of initiation into new-type drug use among adults in Shanghai: are there differences by types of first newtype drug used? Drug Alcohol Depend 2013;131:278-83.
42. McGregor C, Srisurapanont M, Jittiwutikarn J, et al. The nature, time course and severity of methamphetamine withdrawal. Addiction (Abingdon, England) 2005;100:1320-9.
43. Gossop MR, Bradley BP, Brewis RK. Amphetamine withdrawal and sleep disturbance. Drug Alcohol Depend 1982;10:177-83.